Advertisement

Comparison of chlorambucil and Myleran® in chronic lymphocytic and granulocytic leukemia

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ross W.C.J.
        The chemistry of cytotoxic alkylating agents.
        Advances Cancer Res. 1953; 1: 397
        • Ross W.C.J.
        In vitro reactions of biological alkylating agents.
        Ann. New York Acad. Sc. 1958; 68: 669
        • Bergel F.
        Design of alkylating agents for selectivity of action.
        Ann. New York Acad. Sc. 1958; 68: 1238
        • Haddow A.
        • Timmis G.M.
        Myleran in chronic myeloid leukemia: chemical constitution and biological action.
        Lancet. 1953; 1: 207
        • Galton D.A.G.
        Myleran in chronic myeloid leukemia.
        Lancet. 1953; 1: 208
        • Galton D.A.G.
        • Till M.
        Myleran in chronic myeloid leukemia.
        Lancet. 1955; 1: 425
        • Galton D.A.G.
        • Israels L.G.
        • Nabarro J.D.N.
        • Till M.
        Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma.
        Brit. M. J. 1955; 2: 1172
        • Elson L.A.
        A comparison of the effects of radiation and radiomimetic chemicals on the blood.
        Brit. J. Haemat. 1955; 1: 104
        • Elson L.A.
        Hematological effects of the alkylating agents.
        Ann. New York Acad. Sc. 1958; 68: 826
        • Bethell F.H.
        Myleran and triethylene melamine in the treatment of chronic granulocytic leukemia.
        Ann. New York Acad. Sc. 1958; 68: 996
        • Dameshek W.
        • Granville N.B.
        • Rubio Jr., F.
        Therapy of the myeloproliferative disorders with Myleran.
        Ann. New York Acad. Sc. 1958; 68: 1001
        • Galton D.A.G.
        The use of Myleran and similar agents in chronic leukemias.
        Advances Cancer Res. 1956; 4: 73
        • Sykes M.P.
        • Philips F.S.
        • Karnofsky D.A.
        Comparative therapeutic activity of the nitrogen mustards and allied compounds.
        M. Clin. North America. 1956; 68: 837
        • Sykes M.
        Myleran in the treatment of lymphomas.
        Ann. New York Acad. Sc. 1958; 68: 1035
        • Sullivan R.D.
        Myleran therapy in bronchogenic carcinoma.
        Ann. New York Acad. Sc. 1958; 68: 1038
        • Rundles R.W.
        • Coonrad E.V.
        • Willard N.L.
        Summary of results obtained by TEM.
        Ann. New York Acad. Sc. 1958; 68: 926
        • Krakoff L.H.
        • Karnofsky D.A.
        • Burchenal J.H.
        Remissions induced by chlorambucil in chronic granulocytic leukemia.
        J. A. M. A. 1958; 166: 629
        • Cochran W.G.
        Some methods for strengthening the common χ2 tests.
        Biometrics. 1954; 10: 417
        • Freeman G.H.
        • Halton J.H.
        Note on an exact treatment of contingency, goodness of fit and other problems of significance.
        Biometrika. 1951; 38: 141
        • Pillers E.K.
        • Magalini S.I.
        Hematological changes following treatment with p-(di-2-chlorethylamino)-phenylbutyric acid (CB 1348) in cancer.
        Cancer. 1958; 11: 410